<code id='A271E4D442'></code><style id='A271E4D442'></style>
    • <acronym id='A271E4D442'></acronym>
      <center id='A271E4D442'><center id='A271E4D442'><tfoot id='A271E4D442'></tfoot></center><abbr id='A271E4D442'><dir id='A271E4D442'><tfoot id='A271E4D442'></tfoot><noframes id='A271E4D442'>

    • <optgroup id='A271E4D442'><strike id='A271E4D442'><sup id='A271E4D442'></sup></strike><code id='A271E4D442'></code></optgroup>
        1. <b id='A271E4D442'><label id='A271E4D442'><select id='A271E4D442'><dt id='A271E4D442'><span id='A271E4D442'></span></dt></select></label></b><u id='A271E4D442'></u>
          <i id='A271E4D442'><strike id='A271E4D442'><tt id='A271E4D442'><pre id='A271E4D442'></pre></tt></strike></i>

          
          WSS
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge